Imunon Inc
IMNN3.970USD
+0.115+2.98%
Market hours （ET）Quotes delayed by 15 min
7.84MMarket Cap
LossP/E TTM
More Details of Imunon Inc Company
Imunon, Inc. is a clinical-stage biotechnology company. The Company is focused on advancing a portfolio of treatments that harness the body’s natural mechanisms across an array of human diseases. The Company is developing non-viral Deoxyribonucleic acid (DNA) technology across four modalities. The first modality, TheraPlas, is developed for the coding of proteins and cytokines in the treatment of solid tumors. The second modality, PlaCCine, is developed for the coding of viral antigens that can elicit a strong immunological response. The third modality, FixPlas, concerns the application of Imunon’s DNA technology to produce universal cancer vaccines, also called tumor associated antigen cancer vaccines. The fourth modality, IndiPlas, is in the discovery phase and is focused on the development of personalized cancer vaccines, or neoepitope cancer vaccines. Its lead clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer.
Imunon Inc Info
Ticker SymbolIMNN
Company nameImunon Inc
IPO dateOct 27, 1993
CEODr. Stacy R. Lindborg, Ph.D.
Number of employees25
Security typeOrdinary Share
Fiscal year-endOct 27
Address997 Lenox Dr Ste 100
CityLAWRENCEVILLE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code08648
Phone16098969100
Websitehttps://imunon.com/
Ticker SymbolIMNN
IPO dateOct 27, 1993
CEODr. Stacy R. Lindborg, Ph.D.
Company Executives of Imunon Inc
Name
Name/Position
Position
Shareholding
Change
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
5.65K
+6.60%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
4.54K
+402.99%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
4.31K
+119.57%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.82K
+77.50%
Mr. James E. Dentzer
Mr. James E. Dentzer
Independent Director
Independent Director
3.82K
--
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
3.42K
+246.55%
Ms. Christine A. Pellizzari, J.D.
Ms. Christine A. Pellizzari, J.D.
Independent Director
Independent Director
2.58K
--
Ms. Kimberly Graper
Ms. Kimberly Graper
Interim Chief Financial Officer
Interim Chief Financial Officer
--
--
Ms. Susan Eylward
Ms. Susan Eylward
General Counsel, Corporate Secretary
General Counsel, Corporate Secretary
--
--
Dr. Douglas Vincent Faller, M.D., Ph.D.
Dr. Douglas Vincent Faller, M.D., Ph.D.
Chief Medical Officer
Chief Medical Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Michael H. Tardugno
Mr. Michael H. Tardugno
Executive Chairman of the Board
Executive Chairman of the Board
5.65K
+6.60%
Mr. Frederick J. (Fred) Fritz
Mr. Frederick J. (Fred) Fritz
Independent Director
Independent Director
4.54K
+402.99%
Dr. Donald P. Braun, Ph.D.
Dr. Donald P. Braun, Ph.D.
Independent Director
Independent Director
4.31K
+119.57%
Dr. Stacy R. Lindborg, Ph.D.
Dr. Stacy R. Lindborg, Ph.D.
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
3.82K
+77.50%
Mr. James E. Dentzer
Mr. James E. Dentzer
Independent Director
Independent Director
3.82K
--
Dr. Khursheed Anwer, Ph.D.
Dr. Khursheed Anwer, Ph.D.
Executive Vice President, Chief Scientific Officer
Executive Vice President, Chief Scientific Officer
3.42K
+246.55%
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Sabby Management, LLC
3.15%
Renaissance Technologies LLC
2.23%
The Vanguard Group, Inc.
0.67%
Geode Capital Management, L.L.C.
0.51%
Tardugno (Michael H)
0.26%
Other
93.19%
Shareholders
Shareholders
Proportion
Sabby Management, LLC
3.15%
Renaissance Technologies LLC
2.23%
The Vanguard Group, Inc.
0.67%
Geode Capital Management, L.L.C.
0.51%
Tardugno (Michael H)
0.26%
Other
93.19%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
3.88%
Hedge Fund
2.40%
Individual Investor
1.48%
Investment Advisor
0.94%
Research Firm
0.39%
Venture Capital
0.10%
Bank and Trust
0.03%
Other
90.78%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
44
169.61K
7.74%
+38.05K
2025Q2
52
152.78K
6.20%
-44.01K
2025Q1
50
565.85K
3.09%
-1.96M
2024Q4
52
608.75K
4.16%
-1.78M
2024Q3
50
1.20M
8.34%
-536.74K
2024Q2
48
484.50K
4.81%
-359.07K
2024Q1
49
447.12K
4.68%
-585.60K
2023Q4
59
755.78K
7.96%
-79.04K
2023Q3
65
452.55K
4.85%
-471.22K
2023Q2
68
440.18K
4.85%
-489.81K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Sabby Management, LLC
69.00K
3.15%
+69.00K
--
Jun 30, 2025
Renaissance Technologies LLC
48.91K
2.23%
+48.11K
+6006.49%
Jun 30, 2025
The Vanguard Group, Inc.
14.60K
0.67%
+10.86K
+290.27%
Jun 30, 2025
Geode Capital Management, L.L.C.
11.09K
0.51%
+94.00
+0.85%
Jun 30, 2025
Tardugno (Michael H)
5.65K
0.26%
+350.00
+6.60%
May 13, 2025
Fritz (Frederick J)
4.54K
0.21%
+3.63K
+402.99%
Aug 04, 2025
BlackRock Institutional Trust Company, N.A.
4.46K
0.2%
--
--
Jun 30, 2025
Braun (Donald P)
4.31K
0.2%
+2.35K
+119.57%
Aug 04, 2025
Le (Goff Corinne)
4.06K
0.19%
--
--
May 13, 2025
Lindborg (Stacy R)
3.82K
0.17%
+1.67K
+77.50%
Sep 06, 2025
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Date
Type
Ratio
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
Feb 28, 2022
Merger
15→1
